ACM Increases Novanta Stake as Industrial Tech Conviction Grows

American Capital Management Inc. (ACM) has significantly increased its commitment to Novanta Inc. (NOVT), signaling a high-conviction move in the specialized industrial and medical technology sector. According to recent SEC filings, the investment firm added 163,005 shares to its position during the fourth quarter of 2025, a trade valued at approximately $18.56 million based on quarterly average pricing. This aggressive accumulation nearly doubled ACM's exposure to the photonics and precision motion specialist, bringing its total stake to 381,866 shares with a year-end valuation of $45.44 million. The move is particularly noteworthy as it elevates Novanta to a 2% weight within ACM’s $2.27 billion reportable portfolio, highlighting a strategic pivot toward a company that has recently struggled to keep pace with broader market indices.

Novanta operates in a highly technical niche, providing critical components such as laser scanning systems, medical visualization hardware, and precision motion controllers to original equipment manufacturers (OEMs). Its products are foundational to advanced medical procedures and industrial automation, sectors that are increasingly reliant on high-performance subsystems to drive efficiency and accuracy. Despite this technical leadership, Novanta’s stock performance has been lackluster compared to the wider market. As of mid-February 2026, the shares were up only 1% over the preceding 12 months, trailing the S&P 500 by a substantial 10.4 percentage points. ACM’s decision to "double down" suggests that the firm views this price-to-performance gap as a buying opportunity rather than a red flag, likely betting on a cyclical recovery in industrial automation or a breakthrough in medical OEM demand.

“

The move is particularly noteworthy as it elevates Novanta to a 2% weight within ACM’s $2.27 billion reportable portfolio, highlighting a strategic pivot toward a company that has recently struggled to keep pace with broader market indices.

The investment aligns with ACM’s broader portfolio architecture, which favors companies with deep technical moats and mission-critical applications. The firm’s top holdings—including AeroVironment (AVAV), CyberArk (CYBR), and Kratos Defense & Security Solutions (KTOS)—all share a common thread of providing high-specification engineering in sectors with high barriers to entry. By increasing its stake in Novanta, ACM is reinforcing its exposure to the "picks and shovels" of the automation and life sciences industries. While Novanta does not yet sit in the top five holdings, which are currently dominated by aerospace and cybersecurity firms, the scale of the Q4 purchase indicates it is being groomed as a core industrial tech play.

Market observers often interpret such significant institutional buying as a signal of internal confidence that the market is mispricing a company's long-term fundamentals. For Novanta, the challenge lies in translating its sophisticated hardware portfolio into consistent margin expansion and revenue growth that can satisfy Wall Street’s expectations. The company’s focus on high-performance and mission-critical applications provides a degree of insulation from generic commodity cycles, but it remains sensitive to the capital expenditure budgets of its global OEM partners. ACM’s increased position suggests they believe Novanta is at an inflection point, perhaps nearing the end of an inventory correction cycle or poised to benefit from a new generation of medical robotic systems.

Looking ahead, investors should monitor Novanta’s upcoming quarterly earnings for signs of accelerating order books in the life sciences and industrial automation segments. The firm's ability to integrate its photonics and vision capabilities into more comprehensive subsystems will be a key driver of future valuation. For ACM, the success of this trade will depend on Novanta’s ability to close the performance gap with its peers. If the company can leverage its specialized technology to capture a larger share of the growing automation market, ACM’s fourth-quarter accumulation could prove to be a prescient move into a mispriced asset. The firm's willingness to commit nearly $20 million in new capital to a relative laggard underscores a long-term investment horizon that prioritizes technical superiority over short-term price momentum.